Back to top
more

Accuray (ARAY)

(Real Time Quote from BATS)

$2.18 USD

2.18
84,632

-0.04 (-1.80%)

Updated Apr 24, 2024 01:49 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

by Zacks Equity Research

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.

Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q4 Earnings Due on Jan 30: SYK & More

by Indrajit Bandyopadhyay

Fourth-quarter results of Medical Product companies are likely to reflect a year-over-year improvement in revenues. Let's see how SYK, COR and ARAY fare this time around.

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

by Zacks Equity Research

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?

by Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact

by Zacks Equity Research

Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.

Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.

Compared to Estimates, Accuray (ARAY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

by Zacks Equity Research

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

by Zacks Equity Research

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

by Zacks Equity Research

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.

New Strong Sell Stocks for August 11th

by Zacks Equity Research

NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023.

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.

Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cognizant (CTSH) Partners With Accuray to Improve Healthcare

by Zacks Equity Research

Cognizant's (CTSH) partnership agreement will enable Accuray to streamline and drive operational changes to improve patient care.